Skip to content
Disclosery

Vida Ventures Advisors, LLC

Follow

13F filer, CIK 1831423, BOSTON, MA

Vida Ventures Advisors, LLC reported $91,433,096 across 5 holdings for the quarter ended 2024-06-30, in a 13F-HR filed 2024-07-10.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-24-006464

Period
2024-06-30
Reported value
$91.4M
Holdings
5
Top 10 weight
100%
New
0
Sold out
0

Holdings, Q2 2024

Share positions as resolved from 13F-HR 0000950123-24-006464, largest first. % of portfolio is the value over $91,433,096, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
CNTACENTESSA PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 3,931,818 shares; 2024Q1: 3,931,818 shares; 2024Q2: 3,931,818 shares 3,931,818$35.5M38.83%0Timeline
KYTXKYVERNA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: not reported; 2024Q1: 4,523,924 shares; 2024Q2: 4,523,924 shares 4,523,924$33.9M37.11%0Timeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 2,074,787 shares; 2024Q1: 407,499 shares; 2024Q2: 407,499 shares 407,499$14.4M15.73%0Timeline
ALLOALLOGENE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 1,798,163 shares; 2024Q1: 1,798,163 shares; 2024Q2: 1,798,163 shares 1,798,163$4.19M4.58%0Timeline
KRONOS BIO INCKRONOS BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 2,765,314 shares; 2024Q1: 2,765,314 shares; 2024Q2: 2,765,314 shares 2,765,314$3.43M3.75%0

How Q2 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000950123-24-006464 base2024-07-10acceptance time not in the bulk data set